Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Quinidex Articles

AVANIR stock rockets on positive Ph III Zenvia data

12 August 2009

Positive PK data on Avanir's Zenvia

9 June 2008

Avanir's Neurodex sees strong Ph III data

8 May 2006

FDA accepts AVANIR's Neurodex for priority review

10 April 2006

Florida moves on five neg formulary drugs

26 January 2001

FDA backs Pfizer's dofetilide, launch slated for early 2000

11 October 1999

FDA recommends approval of Pfizer's Tikosyn

3 February 1999

Russian Drug Output Fails To Meet Demand

27 January 1997

quinidine warning label discussion

21 August 1995

Copley Receives Approval

13 February 1995

MDR: Misunderstood Drug Resistance?

5 December 1994

AMERICAN HOME HAS CONFIDENCE FOR 1993

12 April 1993

SOTALOL BEST, SAYS ARRHYTHMIA STUDY

27 April 1992

CAST EFFECTS ON ANTI-ARRHYTHMICS

20 January 1992

Showing 1-14 of 14 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • New study shows UCB's Neupro reduces NSBP in RLS patient
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • New study shows UCB's Neupro reduces NSBP in RLS patient

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS